(Q41083185)

English

Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness

scientific article published on September 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

1 reference

based on heuristic

inferred from title

author name string

S S Larsen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

M W Madsen

2

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

B L Jensen

3

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

A E Lykkesfeldt

4

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

language of work or name

0 references

publication date

1 September 1997

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

1129-1136

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Regulation of the secretion of proteins synthesized by the human breast cancer cell line, MCF-7.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Oestrogen receptor: a stable phenotype in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Cathepsin D and breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0215%2819970917%2972%3A6%3C1129%3A%3AAID-IJC31%3E3.0.CO%3B2-X

21 January 2018

Identifiers

10.1002/(SICI)1097-0215(19970917)72:6<1129::AID-IJC31>3.0.CO;2-X

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41083185&oldid=2093400984"